| Jennifer Malloy, PT | |
|
1401 Lincoln Way, Coeur D Alene, ID 83814-2334 | |
| (208) 676-1424 | |
| Not Available |
| Full Name | Jennifer Malloy |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 1401 Lincoln Way, Coeur D Alene, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144274598 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT-1627 (Idaho) | Primary |
| Provider Name | Kitsap Physical Therapy And Sports Clinic Ps Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1912902347 PECOS PAC ID: 6507762333 Enrollment ID: O20031211000242 |
News Archive
Results from early phase trials investigating different therapeutic agents in lung cancer patients were presented during the third Presidential Session at the European Cancer Congress in Vienna, Austria. Here we summarise two studies reported at the session.
Environmental health advocates hope that U.S. FDA will make its promised announcement about health hazards of bisphenol A (BPA), a synthetic sex hormone linked to cancer, behavioral changes, reproductive harm and other illnesses, in time for Christmas.
As the prevalence of overweight and obesity increases among American children, signs of risk for chronic diseases such as type 2 diabetes and cardiovascular diseases - previously thought of as adult disorders - are on the rise among youth.
The Vision Center at Childrens Hospital Los Angeles has been awarded a $1 million grant from the National Cancer Institute (NCI) to conduct a clinical trial on a new drug delivery system to treat young children diagnosed with retinoblastoma. The device is designed to deliver chemotherapy through a tiny silicone cup sealed to the outer surface (sclera) of the eye, which can more directly target cancer cells and greatly reduce the side effects caused by current chemotherapy treatments.
Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Malloy, PT 2400 Nw Myhre Rd, Ste 101, Silverdale, WA 98383 Ph: (360) 598-3764 | Jennifer Malloy, PT 1401 Lincoln Way, Coeur D Alene, ID 83814-2334 Ph: (208) 676-1424 |
News Archive
Results from early phase trials investigating different therapeutic agents in lung cancer patients were presented during the third Presidential Session at the European Cancer Congress in Vienna, Austria. Here we summarise two studies reported at the session.
Environmental health advocates hope that U.S. FDA will make its promised announcement about health hazards of bisphenol A (BPA), a synthetic sex hormone linked to cancer, behavioral changes, reproductive harm and other illnesses, in time for Christmas.
As the prevalence of overweight and obesity increases among American children, signs of risk for chronic diseases such as type 2 diabetes and cardiovascular diseases - previously thought of as adult disorders - are on the rise among youth.
The Vision Center at Childrens Hospital Los Angeles has been awarded a $1 million grant from the National Cancer Institute (NCI) to conduct a clinical trial on a new drug delivery system to treat young children diagnosed with retinoblastoma. The device is designed to deliver chemotherapy through a tiny silicone cup sealed to the outer surface (sclera) of the eye, which can more directly target cancer cells and greatly reduce the side effects caused by current chemotherapy treatments.
Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).
› Verified 6 days ago
Mark Andrew Stevens, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1812 N Lakewood Dr Ste 100, Coeur D Alene, ID 83814 Phone: 208-966-4475 Fax: 208-966-4475 | |
Mrs. Holly D Bruns, M.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 500 W Aqua Ave, Coeur D Alene, ID 83815 Phone: 208-762-1122 | |
Dr. Sharron Elizabeth Mcmillan, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 411 W Haycraft Ave Ste D4, Coeur D Alene, ID 83815 Phone: 208-664-2468 | |
Jonathan Hoelzen, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1088 W Prairie Ave, Coeur D Alene, ID 83815 Phone: 208-772-6609 | |
Competitive Fitness & Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1321 W Northwood Center Ct, Suite B, Coeur D Alene, ID 83814 Phone: 208-665-7055 Fax: 208-665-7093 | |
Pure Inc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3655 N Government Way, Suite 3, Coeur D Alene, ID 83815 Phone: 208-691-8888 | |
Debora Caires Nelson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2200 Ironwood Pl, Coeur D Alene, ID 83814 Phone: 208-667-6486 Fax: 208-676-8276 |